PPPriyanka N. Prem

Priyanka N. Prem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Priyanka N. Prem has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Preparation of fisetin loaded mesoporous silica nanocarrier to attenuate ischemia reperfusion injury

    by Priyanka N. Prem, Kiran Kumar Balu, Sakthivel Gandhi, Gino A. Kurian


  • Evaluation of prophylactic efficacy of sodium thiosulfate in combating I/R injury in rat brain: exploring its efficiency further in vascular calcified brain slice model

    by Keerthana Baskaran, Jefri Thimoathi Johnson, Priyanka N Prem, Sriram Ravindran, Gino A Kurian

    Cerebral ischemia reperfusion injury (CIR) is one of the clinical manifestations encountered during the management of stroke. High prevalence of intracranial arterial calcification is reported in stroke patients. However, the impact of vascular calcification (VC) in the outcome of CIR and the efficacy of mechanical preconditioning (IPC) and pharmacological conditioning with sodium thiosulphate (STS) in ameliorating IR remains unclear. Two experimental models namely carotid artery occlusion (n = 36) and brain slice models (n = 18) were used to evaluate the efficacy of STS in male Wistar rats. IR was inflicted in rat by occluding carotid artery for 30 min followed by 24-h reperfusion after STS (100 mg/kg) administration. Brain slice model was used to reconfirm the results to account blood brain barrier permeability. Further, brain slice tissue was utilised to evaluate the efficacy of STS in VC rat brain by measuring the histological alterations and biochemical parameters. Pre-treatment of STS prior to CIR in intact animal significantly reduced the IR-associated histopathological alterations in brain, declined oxidative stress and improved the mitochondrial function found to be similar to IPC. Brain slice model data also confirmed the neuroprotective effect of STS similar to IPC in IR challenged tissue slice. Higher tissue injury was noted in VC brain IR tissue than normal IR tissue. Therapeutic efficacy of STS was evident in VC rat brain tissues and normal tissues subjected to IR. On the other hand, IPC-mediated protection was noted only in IR normal and adenine-induced VC brain tissues not in high-fat diet (HFD) induced VC brain tissues. Based on the results, we concluded that similar to IPC, STS was effective in attenuating IR injury in CIR rat brain. Vascular calcification adversely affected the recovery protocol of brain tissues from ischemic insult. STS was found to be an effective agent in ameliorating the IR injury in both adenine and HFD induced vascular calcified rat brain, but IPC-mediated neuroprotection was absent in HFD-induced VC brain tissues.


  • Open Access

    A Study on the Therapeutic Effect of 5-Azacytidine to Attenuate the Ramifying Repercussions of Ischemia Reperfusion Injury on Mitochondrial Molecular Machinery

    by Vasisht Yegneshwaran, Priyanka N Prem, Sri Rahavi Boovarahan, Gino A Kurian

    5-Azacytidine is a hypomethylating agent that has for long been used in cancer therapy due to its ability to inhibit the protein DNA methyltransferase responsible for hyper-methylating DNA strands. Recently, studies involving in vitro, ex vivo, and in vivo experiments have assessed the cardioprotective effects of 5-Azacytidine during myocardial ischemia-reperfusion injury (IRI). However, the effect of this compound in restoring the damage induced to mitochondrial molecular machinery during IRI has not yet been explored. Understanding this would help us analyze the ways through which mito-targeted therapeutics can be used. The purpose of this study is to investigate the therapeutic impact of 5-Azacytidine, as DNA methylation is a very common epigenetic modification observed during IRI. Furthermore, the protective effect of the compound in alleviating the damage induced to mitochondria during IRI can be identified, as DNA methylation can leave a direct impact on the mitochondrial genes as well. An isolated mitochondria model will be used to determine the effects of 5-Azacydine on mitochondrial molecular machinery as the capacity to generate DNA, RNA, and proteins are preserved in isolated mitochondria. In this study, we focus on the mechanisms of mitochondrial replication, and translation to understand the effect of 5-Azacytidine on the IRI affected mitochondrial system. Mitochondrial dysfunction is also another key turn of events that happens during IRI. The role of 5-Azacyidine in preserving the functionality is also being assessed in our research. The findings of these experiments would help us determine the plasticity the compound imparts on mitochondrial molecular mechanism’s integrity and function post-induced IRI.

  • Long-term administration of fisetin was not as effective as short term in ameliorating IR injury in isolated rat heart

    by Priyanka N. Prem, Bhavana Sivakumar, Sri Rahavi Boovarahan, Gino A. Kurian

    The current study aims to determine the comparative efficacy of fisetin in reducing myocardial ischemia–reperfusion injury (IR) in isolated rat hearts when the drug was given either oral or intraperitoneal (ip) for short-term and long-term administration. Rats treated with fisetin (20 mg/kg-oral/ip) for short (30 min prior to surgery) and long (15 days prior to surgery followed by 1-day washout) duration were subjected to myocardial IR using Langendorf perfusion system. Hemodynamics, cardiac injury, mitochondrial functional assessment, and fisetin levels were estimated. Unlike the long-term administration of fisetin, the short-term treated-rat heart exhibited significant cardioprotection, measured via hemodynamic indices (RPP in mmHg × beats/min × 10 ^ 4: IR — 4 ± 0.1, FIPS — 2.49 ± 0.18, FIPL — 1.87 ± 0.14), reduced infarct size (in % area of infarct: IR — 38 ± 5, FIPS — 17 ± 1, FOS — 14 ± 2), improved mitochondrial ETC enzyme activity (NQR activity in IFM: FIPS — 0.25 ± 0.016, FIPL — 0.20 ± 0.02), and declined oxidative stress (GSH in IFM: FIPS — 1.52 ± 0.14, FIPL — 1.25 ± 0.22). However, no significant difference in the protection was observed between the animals treated with oral or intraperitoneally administered fisetin. Single dose of fisetin administration before IR protocol was more effective than 15 days of fisetin-treated drug followed by 1-day washout, thus may not be suitable for long-term dietary supplement for post-surgical cardiac rehabilitation.


  • FIsetin Preserves Interfibrillar Mitochondria to Protect Against Myocardial Ischemia-Reperfusion Injury

    by Karthi Shanmugam, Priyanka N Prem, Sri Rahavi Boovarahan, Bhavana Sivakumar, Gino A. Kurian

    According to our previous study, fisetin (3,3’,4’,7-tetrahydroxyflavone), a bioactive phytochemical (flavonol), reportedly showed cardioprotection against ischemia-reperfusion injury (IRI) by reducing oxidative stress and inhibiting glycogen synthase kinase 3β (GSK3β) [1]. GSK3β is said to exert a non-mitochondrial mediated cardioprotection; therefore, distinct mechanisms of GSK3β on the regulatory effect of mitochondria need to be addressed. The two distinct mitochondrial subpopulations in the heart, namely interfibrillar mitochondria (IFM) and subsarcolemmal mitochondria (SSM), respond differently to disease states. The current study aimed to understand the effect of fisetin on the subpopulation-specific preservation of IFM and SSM while rendering cardioprotection against ischemia reperfusion (I/R). Rats were pre-treated with fisetin (20 mg/kg) intraperitoneally, and IRI was induced using Langendorff isolated heart perfusion technique. Hemodynamic parameters were recorded, and the cardiac injury was assessed using infarct size (IS), lactate dehydrogenase (LDH), and creatine kinase (CK) levels. Subpopulation-specific mitochondrial preservation was evaluated by electron transport chain (ETC), catalase, superoxide dismutase (SOD), and glutathione (GSH) activities. The bioavailability of fisetin in IFM and SSM was measured using the fluorescence method. The ability of fisetin to bind directly to the mitochondrial complex-1 and activating it through donating electrons to FMN was studied using molecular docking studies and further validated by in vitro rotenone sensitivity assay. Cardioprotective effects exhibited by fisetin were mainly mediated through IFM preservation. Mitochondrial bioavailability of fisetin is more in IFM than SSM in both ex vivo and in vitro conditions. Fisetin increased mitochondrial ATP production in I/R insult hearts by activating ETC complex 1. Inhibition of complex 1 prevents the ATP-producing capacity of fisetin. Our results provide evidence that fisetin plays a protective role in myocardial IRI, possibly by preserving the functional activities of IFM.